This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database.
All Wales Medicines Strategy Group (AWMSG). Teriparatide (Forsteo®) for the treatment of osteoporosis in men at increased risk of fracture. Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG Secretariat Assessment Report Advice No. 2108. 2008
Teriparatide (Forsteo®) is not recommended for use within NHS Wales for the treatment of osteoporosis in men at increased risk of fracture.
Subject indexing assigned by CRD
Bone Density Conservation Agents; Males; Osteoporosis; Risk Factors; Teriparatide
Country of organisation
An English language summary is available.
Address for correspondence
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road,
Penarth, Vale of Glamorgan CF64 2XX
Date abstract record published